Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX208 in BRAF V600-mutant advanced non-small cell lung cancer
CTR20212076Phase 2Terminated
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX208 in non-small cell lung cancer (NSCLC), sponsored by Suzhou Runxin Biotechnology. Started Nov 2021; status: terminated.
02
Drugs
HLX208
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212076.